Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483067 · ClinicalTrials.gov registry record · Phase 2
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00483067: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00483067 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00483067, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the response rate, progression-free survival (PFS) and overall survival of patients who receive 2-CdA + Ara-C. 2. To examine if there is any clonality in the cytokine expression of helper T cells or cytokine receptor expression of eosinophils. 3. To determine the effect of 2-CdA on accumulation of Ara-C triphosphate in eosinophils.
Interventions
- DRUG Ara-C
- DRUG 2-CdA
- DRUG G-CSF (Granulocyte colony-stimulating factor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1998-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483067
The ClinicalTrials.gov registry entry for NCT00483067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ara-C is the first listed.
NCT00483067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483067 about?
NCT00483067 is a clinical study titled "2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)". Primary Objectives: 1. To determine the response rate, progression-free survival (PFS) and overall survival of patients who receive 2-CdA + Ara-C. 2. To examine if there is any clonality in the cytokine expression of helper T cells or cytokine receptor expression of eosinophils. 3. To determine the...
What is the current status of trial NCT00483067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 1998-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00483067?
The interventions under investigation include: Ara-C (DRUG), 2-CdA (DRUG), G-CSF (Granulocyte colony-stimulating factor) (DRUG).
Who is sponsoring clinical trial NCT00483067?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.